{"id":"W4220822578","doi":"10.1200/jco.21.02011","title":"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"University of Michigan Comprehensive Cancer Center; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; University of Florida Health; Genentech; National Institutes of Health; University of California, San Francisco; Barbara Ann Karmanos Cancer Institute; University of Arkansas for Medical Sciences; Hamilton Health Sciences; University of South Alabama; Florida Department of Health; Sidney Kimmel Comprehensive Cancer Center; West Virginia University; National Cancer Institute; Cleveland Clinic; NRG Oncology; Incyte; Medical College of Wisconsin; Wayne State University; AstraZeneca","keywords":"Olaparib; Ovarian cancer; Chemotherapy; Paclitaxel; Phases of clinical research; Germline","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002128117,0.001613285,0.002164602,0.0004518355,0.0003977309,0.00102905,0.001137791,0.001777586,0.006647981],"category_scores_gemma":[0.002564497,0.0005253559,0.001762782,0.0004624041,0.001243043,0.0009286157,0.0003684382,0.002454219,0.0007893882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001224609,"about_ca_system_score_gemma":0.001709878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001139123,"about_ca_topic_score_gemma":0.003400679,"domain_scores_codex":[0.999283,0.000448602,0.00003418916,0.0001093945,0.00004902048,0.00007578862],"domain_scores_gemma":[0.9987379,0.000420548,0.0002772158,0.00008798451,0.00005920305,0.0004172824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9674276,0.008304336,0.0006389011,0.0006489611,0.0006584971,0.00005417778,0.00004135645,0.0004359616,0.00150474,0.0001528764,0.001352733,0.0187799],"study_design_scores_gemma":[0.9678704,0.03060674,0.0004730262,0.00002412852,0.0001852248,0.00002160523,0.000009839649,0.0002321437,0.0001056175,0.0001121515,0.0003528033,0.000006381458],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797931,0.006240366,0.0007011516,0.001438089,0.0007845863,0.006671044,0.001427743,0.0002101921,0.002733881],"genre_scores_gemma":[0.9785507,0.003559452,0.002414815,0.001985777,0.0007334273,0.007441318,0.00144901,0.00002647248,0.003838974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006647981,"threshold_uncertainty_score":0.02223969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2337045487282843,"score_gpt":0.5331871418585143,"score_spread":0.2994825931302301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}